Literature DB >> 33061481

Estimating the Prevalence and Mortality of Coronavirus Disease 2019 (COVID-19) in the USA, the UK, Russia, and India.

Yongbin Wang1, Chunjie Xu2, Sanqiao Yao1, Yingzheng Zhao1, Yuchun Li1, Lei Wang3, Xiangmei Zhao1.   

Abstract

OBJECTIVE: The aim of this study is to apply the advanced error-trend-seasonal (ETS) framework to forecast the prevalence and mortality series of COVID-19 in the USA, the UK, Russia, and India, and the predictive performance of the ETS framework was compared with the most frequently used autoregressive integrated moving average (ARIMA) model.
MATERIALS AND METHODS: The prevalence and mortality data of COVID-19 in the USA, the UK, Russia, and India between 20 February 2020 and 15 May 2020 were extracted from the WHO website. Then, the data subsamples between 20 February 2020 and 3 May 2020 were treated as the training horizon, and the others were used as the testing horizon to construct the ARIMA models and the ETS models.
RESULTS: Based on the model evaluation criteria, the ARIMA (0,2,1) and ETS (M,MD,N), sparse coefficient ARIMA (0,2,(1,6)) and ETS (A,AD,M), ARIMA (1,1,1) and ETS (A,MD,A), together with ARIMA (2,2,1) and ETS (A,M,A) specifications were identified as the preferred ARIMA and ETS models for the prevalence data in the USA, the UK, Russia, and India, respectively; the ARIMA (0,2,1) and ETS (M,A,M), ARIMA (0,2,1) and ETS (M,A,N), ARIMA (0,2,1) and ETS (A,A,N), coupled with ARIMA (0,2,2) and ETS (M,M,N) specifications were selected as the optimal ARIMA and ETS models for the mortality data in these four countries, respectively. Among these best-fitting models, the ETS models produced smaller forecasting error rates than the ARIMA models in all the datasets.
CONCLUSION: The ETS framework can be used to nowcast and forecast the long-term temporal trends of the COVID-19 prevalence and mortality in the USA, the UK, Russia, and India, and which provides a notable performance improvement over the most frequently used ARIMA model. Our findings can aid governments as a reference to prepare for and respond to the COVID-19 pandemic both in restricting the transmission of the disease and in lowering the disease-related deaths in the upcoming days.
© 2020 Wang et al.

Entities:  

Keywords:  ARIMA model; ETS model; coronavirus disease 2019; epidemiological indicators; nowcasting; outbreak

Year:  2020        PMID: 33061481      PMCID: PMC7532899          DOI: 10.2147/IDR.S265292

Source DB:  PubMed          Journal:  Infect Drug Resist        ISSN: 1178-6973            Impact factor:   4.003


  38 in total

1.  Epidemiological analysis of hemorrhagic fever with renal syndrome in China with the seasonal-trend decomposition method and the exponential smoothing model.

Authors:  Guibao Ke; Yao Hu; Xin Huang; Xuan Peng; Min Lei; Chaoli Huang; Li Gu; Ping Xian; Dehua Yang
Journal:  Sci Rep       Date:  2016-12-15       Impact factor: 4.379

2.  When will the battle against novel coronavirus end in Wuhan: A SEIR modeling analysis.

Authors:  Kangkang Wan; Jing Chen; Changming Lu; Lanlan Dong; Zhicheng Wu; Lianglu Zhang
Journal:  J Glob Health       Date:  2020-06       Impact factor: 4.413

3.  Real-time forecasts and risk assessment of novel coronavirus (COVID-19) cases: A data-driven analysis.

Authors:  Tanujit Chakraborty; Indrajit Ghosh
Journal:  Chaos Solitons Fractals       Date:  2020-04-30       Impact factor: 5.944

4.  Estimation of COVID-19 prevalence in Italy, Spain, and France.

Authors:  Zeynep Ceylan
Journal:  Sci Total Environ       Date:  2020-04-22       Impact factor: 7.963

5.  Secular Seasonality and Trend Forecasting of Tuberculosis Incidence Rate in China Using the Advanced Error-Trend-Seasonal Framework.

Authors:  Yongbin Wang; Chunjie Xu; Jingchao Ren; Weidong Wu; Xiangmei Zhao; Ling Chao; Wenjuan Liang; Sanqiao Yao
Journal:  Infect Drug Resist       Date:  2020-03-05       Impact factor: 4.003

6.  Comparison of ARIMA and GM(1,1) models for prediction of hepatitis B in China.

Authors:  Ya-Wen Wang; Zhong-Zhou Shen; Yu Jiang
Journal:  PLoS One       Date:  2018-09-04       Impact factor: 3.240

7.  Trend and forecasting of the COVID-19 outbreak in China.

Authors:  Qiang Li; Wei Feng; Ying-Hui Quan
Journal:  J Infect       Date:  2020-02-27       Impact factor: 6.072

8.  Mathematic modeling of COVID-19 in the United States.

Authors:  Yuanji Tang; Shixia Wang
Journal:  Emerg Microbes Infect       Date:  2020-12       Impact factor: 7.163

9.  A mathematical model for simulating the phase-based transmissibility of a novel coronavirus.

Authors:  Tian-Mu Chen; Jia Rui; Qiu-Peng Wang; Ze-Yu Zhao; Jing-An Cui; Ling Yin
Journal:  Infect Dis Poverty       Date:  2020-02-28       Impact factor: 4.520

10.  Application of the ARIMA model on the COVID-2019 epidemic dataset.

Authors:  Domenico Benvenuto; Marta Giovanetti; Lazzaro Vassallo; Silvia Angeletti; Massimo Ciccozzi
Journal:  Data Brief       Date:  2020-02-26
View more
  4 in total

1.  Estimating the Effects of the COVID-19 Outbreak on the Reductions in Tuberculosis Cases and the Epidemiological Trends in China: A Causal Impact Analysis.

Authors:  Wenhao Ding; Yanyan Li; Yichun Bai; Yuhong Li; Lei Wang; Yongbin Wang
Journal:  Infect Drug Resist       Date:  2021-11-06       Impact factor: 4.003

2.  Estimating the Long-Term Epidemiological Trends and Seasonality of Hemorrhagic Fever with Renal Syndrome in China.

Authors:  Yuhan Xiao; Yanyan Li; Yuhong Li; Chongchong Yu; Yichun Bai; Lei Wang; Yongbin Wang
Journal:  Infect Drug Resist       Date:  2021-09-21       Impact factor: 4.003

3.  Forecasting COVID-19 pandemic in Alberta, Canada using modified ARIMA models.

Authors:  Jian Sun
Journal:  Comput Methods Programs Biomed Update       Date:  2021-09-26

4.  Time Series Analysis and Forecasting of the Hand-Foot-Mouth Disease Morbidity in China Using An Advanced Exponential Smoothing State Space TBATS Model.

Authors:  Chongchong Yu; Chunjie Xu; Yuhong Li; Sanqiao Yao; Yichun Bai; Jizhen Li; Lei Wang; Weidong Wu; Yongbin Wang
Journal:  Infect Drug Resist       Date:  2021-07-21       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.